Zevra Therapeutics, Inc. (ZVRA) Stock Price & Analysis
Zevra Therapeutics, Inc. (ZVRA) closed at USD 10.27 on Thursday, October 15, 2026, up 0.39% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 10.23; the Oct 15, 2026 session ranged USD 10.22–10.6 on volume of 462,448 shares. Market capitalization is $609.87M, with a 52-week range of USD 8.01–15.04 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ZVRA.md
Key facts (ZVRA)
- Analysts: Buy (mean 1.78 on a 1–5 scale) (9 analysts), mean target USD 25 (range 20–35).
- Total return with dividends: 1Y -9.8% vs S&P 500 +18.1%; 5Y +5.1% vs S&P 500 +85.1%.
- Next earnings: 2026-11-04, EPS estimate USD 0.18, revenue estimate $37.4M.
Analysts (ZVRA)
Consensus Buy (mean 1.78 on a 1–5 scale), 9 analysts; mean target USD 25 (low 20, high 35).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-20 | HC Wainwright & Co. | Reiterated | Buy | $26 |
| 2026-08-07 | Guggenheim | Target lowered | Buy | $24 → $23 |
| 2026-08-06 | Citizens | Target raised | Market Outperform | $25 → $28 |
| 2026-07-27 | Canaccord Genuity | Target lowered | Buy | $29 → $20 |
| 2026-07-27 | Guggenheim | Target lowered | Buy | $29 → $24 |
| 2026-07-27 | BTIG | Target lowered | Buy | $27 → $24 |
| 2026-06-23 | HC Wainwright & Co. | Reiterated | Buy | $26 |
Total return (dividends reinvested) (ZVRA)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -9.8% | +5.1% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -9.8% | +1.0% |
| Volatility (annualized) | 60.8% | 59.8% |
| Max drawdown | -35.5% (Jul 2026→Jul 2026) | -59.4% (Oct 2021→May 2022) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 10.27 |
|---|---|
| Change | ▲ 0.39% (up) |
| Previous Close | USD 10.23 |
| Open | USD 10.4 |
| Day Range | USD 10.22 – 10.6 |
| 52-Week Range | USD 8.01 – 15.04 |
| Volume | 462,448 shares |
| Market Cap | $609.87M |
| Exchange | NMS |
Technical Analysis (ZVRA)
Nexqual's technical model rates ZVRA "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 39.32 (neutral) |
| vs SMA50 | Below (USD 11.49) |
| MACD | -0.3 (negative) |
Analyst Ratings (ZVRA)
Wall Street analysts rate ZVRA "Buy" based on 9 analysts, with a mean price target of USD 25 (range USD 20–35), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 25 |
| High Target | USD 35 |
| Low Target | USD 20 |
| Buy / Hold / Sell | 9 / 0 / 0 |
Earnings (ZVRA)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD 0.18 |
| Revenue Estimate | $37.41M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.25 vs est 0.18 ▲ beat |
| 2026-03-31 | USD 0.18 vs est 0.08 ▲ beat |
| 2025-12-31 | USD 0.19 vs est 0.05 ▲ beat |
| 2025-09-30 | USD -0.01 vs est -0.02 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (ZVRA)
| Total Revenue | $136.07M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +53.30% |
| Gross Margin | +95.46% |
| Operating Margin | +42.30% |
| Profit Margin | +42.82% |
| ROE | +34.80% |
| Debt / Equity | 0.01 |
| Current Ratio | 5.17 |
| Total Cash | $221.57M |
| Total Debt | $1.50M |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (ZVRA)
Nexqual rates Zevra Therapeutics, Inc.'s overall financial health "Strong" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Strong — Revenue +351% YoY (annual) |
|---|---|
| Profitability | Strong — Operating margin 42% |
| Balance Sheet | Strong — $222M cash vs $1M debt, net cash position |
| Cash Flow | Solid — Operating cash flow $33M (TTM) |
| Efficiency | Strong — ROE 35%, ROA 8.7% |
Ownership (ZVRA)
| Insider Ownership | +1.31% |
|---|---|
| Institutional Ownership | +77.67% |
| Shares Outstanding | 59.38M |
| Float | 53.87M |
| Short % of Float | +12.17% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (ZVRA)
Zevra Therapeutics, Inc. is led by Neil F. McFarlane (age 52), President, CEO & Director, per Nexqual as of October 16, 2026 at 05:22 UTC.
| President, CEO & Director | Neil F. McFarlane (age 52) |
|---|---|
| CFO & Treasurer | Justin A. Renz (age 53) |
| Vice President of Investor Relations & Corporate Communications | Nichol L. Ochsner |
Major Backers & Investors (ZVRA)
Notable institutional backers of Zevra Therapeutics, Inc. include Nantahala Capital Management, LLC, Shaw D.E. & Co., Inc., Qube Research & Technologies Ltd, according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Nantahala Capital Management, LLC | 41.66% |
| Shaw D.E. & Co., Inc. | 30.29% |
| Qube Research & Technologies Ltd | 28.77% |
| Morgan Stanley | 27.9% |
| Janus Detroit Street TRT-Janus Henderson Small/Mid Cap Growth Alpha ET | 15.53% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 35.71% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt